| IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors (NCT05076591) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-06-20 |
| Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping. (NCT06376773) | Fujian Medical University | 2022-06-01 |
| A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma (NCT04799548) | Shanghai Zhongshan Hospital | 2021-12-30 |
| IMC001 for Clinical Research on Advanced Digestive System Malignancies (NCT05028933) | Zhejiang University | 2021-09-30 |
| Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC (NCT04890392) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-01-15 |
| A Randomized Controlled Trial of Integrated Early Palliative Care for Advanced Gastric Cancer Patients (NCT05584592) | Yonsei University | 2020-07-01 |
| Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer (NCT04195828) | Fujian Medical University | 2020-06-18 |
| Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer (NCT04286711) | China Medical University, China | 2020-03-01 |
| A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination (NCT04797923) | Gangnam Severance Hospital | 2019-12-01 |
| Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer (NCT04182724) | Chinese PLA General Hospital | 2019-11-12 |
| Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer (NCT04385641) | Shandong Golden Brick Biotechnology Co., Ltd. | 2019-10-08 |
| Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer (NCT03954756) | Henan Cancer Hospital | 2019-06-01 |
| Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer (NCT03579784) | Do-Youn Oh | 2018-11-26 |
| Lenvatinib and Pembrolizumab Simultaneous Combination Study (NCT03609359) | National Cancer Center Hospital East | 2018-10-03 |
| Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients (NCT03564834) | Peking University | 2018-08-23 |
| A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor (NCT03393416) | HRYZ Biotech Co. | 2018-04-19 |
| Comparison of Ability of pCLE and WLE for Diagnosis and Cancer Tissue Acquisition in Advanced Gastric Cancer After Chemotherapy Status (NCT03449966) | Yonsei University | 2018-02-20 |
| Bioinformation Therapy for Gastric Cancer (NCT03350477) | Fuda Cancer Hospital, Guangzhou | 2017-11-30 |
| A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (NCT03223376) | Hutchison Medipharma Limited | 2017-10-18 |
| Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer (NCT03137004) | Fujian Cancer Hospital | 2017-06-01 |
| Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer (NCT03255811) | DongMa | 2017-03-25 |
| A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (NCT02935634) | Bristol-Myers Squibb | 2016-11-29 |
| Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 (NCT02952729) | Mersana Therapeutics | 2016-11-21 |
| Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer (NCT02873520) | Ningbo Cancer Hospital | 2016-08-01 |
| A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy (NCT02560740) | SMR Biotech Co., Ltd. | 2016-03-01 |
| A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer (NCT01946061) | Yonsei University | 2015-05-01 |
| Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy (NCT02451956) | Samsung Medical Center | 2015-01-07 |
| Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching Analysis (NCT06941168) | Fujian Medical University | 2015-01-01 |
| The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer (NCT02038621) | The Second People's Hospital of Sichuan | 2014-01-01 |
| Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer (NCT02123407) | Peking University | 2013-12-01 |
| Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer (NCT02072317) | Fudan University | 2013-11-01 |
| A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China (NCT01472250) | Peking University | 2011-11-01 |
| Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients (NCT01402401) | Novartis Pharmaceuticals | 2011-11-01 |
| FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer (NCT01503372) | Charite University, Berlin, Germany | 2011-11-01 |
| A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy (NCT01248403) | Krankenhaus Nordwest | 2011-10-01 |
| Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer (NCT01206218) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2010-10-01 |
| Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer (NCT01471470) | Asan Medical Center | 2010-07-01 |
| PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer (NCT01152853) | Seoul National University Hospital | 2010-07-01 |
| Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer (NCT01084330) | Novartis Pharmaceuticals | 2010-04-01 |
| RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX (NCT01049620) | Asan Medical Center | 2010-02-01 |
| Venous Thromboembolism in Advanced Gastric Cancer Patients (NCT01047618) | Asan Medical Center | 2009-12-01 |
| Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (NCT01015339) | Peking University | 2009-11-01 |
| Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer (NCT00992199) | Fudan University | 2009-08-01 |
| Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (NCT00879333) | Novartis Pharmaceuticals | 2009-07-01 |
| Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer (NCT00842244) | Pfizer | 2009-04-01 |
| Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer (NCT00845884) | Rabin Medical Center | 2009-02-01 |
| Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS (NCT00915382) | Asan Medical Center | 2009-01-01 |
| Efficacy Study of TKcell in Advanced Gastric Cancer (NCT00854854) | Binex | 2009-01-01 |
| Laparoscopic Gastrectomy for Advanced Gastric Cancer (NCT01441336) | Seoul National University Bundang Hospital | 2008-11-01 |
| Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer (NCT00842491) | Peking University | 2008-11-01 |
| Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis (NCT02071043) | Shanghai Zhongshan Hospital | 2008-11-01 |
| Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer (NCT00821990) | Samsung Medical Center | 2008-09-01 |
| Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC) (NCT00743964) | Samsung Medical Center | 2008-04-01 |
| Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction (NCT01042782) | Krankenhaus Nordwest | 2008-01-01 |
| Paclitaxel and Irinotecan in Advanced Gastric Cancer (NCT01136031) | Seoul National University Hospital | 2008-01-01 |
| Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP (NCT00565370) | Asan Medical Center | 2007-11-01 |
| Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer (NCT00519324) | Novartis Pharmaceuticals | 2007-08-01 |
| A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. (NCT00428220) | Pfizer | 2007-07-01 |
| Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin (NCT00976768) | Asan Medical Center | 2004-10-01 |
| A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer (NCT01851941) | Seoul National University Hospital | 2004-10-01 |
| Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer (NCT02142322) | Seoul National University Hospital | 2004-06-01 |